Skip to main content

Advertisement

Table 1 Clinical demographics of multiple sclerosis patients and healthy controls

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

  Untreated MS (n = 35) MS w/ IFN-β (n = 21) HCs (n = 44) p value
Untreated MS vs. HCs MS w/ IFN-β vs. HCs Untreated MS vs. MS w/ IFN-β
Female, n (%) 30 (85.7) 15 (71.4) 27 (61.4) 0.023 NS NS
Age at examination, years 50.0 (37.0–59.0) 45.0 (42.5–48.5) 35.0 (32.3–43.8) < 0.001 < 0.001 NS
Age at disease onset, years 31.0 (24.0–37.0) 30.0 (24.0–34.0) NS
Disease duration at examination, years 13.6 (7.80–20.9) 15.4 (10.7–20.8) NS
Subtype (RRMS / SPMS / PPMS), n (%) 26/6/3 (74.3/17.1/8.6) 13/7/1 (61.9/33.3/4.8) NS
EDSS score at examination 2.0 (1.0–4.5) 3.0 (1.75–6.0) NS
MSSS at examination 2.44 (0.38–6.46) 2.93 (1.00–7.15) NS
Disease duration at IFN-β initiation, years 6.58 (1.92–12.1)
EDSS score at IFN-β initiation 2.5 (1.75–5.25)
MSSS at IFN-β initiation 5.24 (2.38–7.56)
Years of IFN-β treatment 7.0 (5.0–10.0)
  1. Values are the median (IQR) or count (%)
  2. EDSS Expanded Disability Status Scale, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, MS multiple sclerosis, MSSS MS severity score, NS not significant, PPMS primary progressive MS, RRMS relapsing-remitting MS, SPMS secondary progressive MS, w/ with